Research programme: nuclear receptor modulators - Allergan

Drug Profile

Research programme: nuclear receptor modulators - Allergan

Alternative Names: AGN193198

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan
  • Class Small molecules
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators; Retinoic acid receptor agonists; Retinoic acid receptor antagonists; Retinoid X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Neutropenia

Most Recent Events

  • 24 Mar 2008 NRX 4204 has moved into clinical development
  • 18 May 2007 Vitae Pharmaceuticals sublicenses rights to this research programme to Quest Group International
  • 16 Aug 2005 Preclinical trials in Neutropenia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top